In8Bio (INAB) Debt Ratio (2020 - 2021)
In8Bio (INAB) posted Debt Ratio of 0.01 for Q2 2021, up 19.05% sequentially from 0.01 in Q4 2020.
In8Bio (INAB) Debt Ratio (2020 - 2021) Analysis & Trends
In8Bio has reported Debt Ratio for 2 years, with the latest figure at 0.01 in Q2 2021.
- Quarterly Debt Ratio changed N/A year-over-year to 0.01 in Q2 2021, while the trailing twelve-month figure through Jun 2021 was 0.01 (changed N/A YoY) and the FY2020 annual result came in at 0.01, changed N/A from the prior year.
- Debt Ratio grew to 0.01 in Q2 2021 per INAB's latest filing, from 0.01 in the prior quarter.
- Over five years, Debt Ratio peaked at 0.01 in Q2 2021 and troughed at 0.01 in Q4 2020.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Debt Ratio (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.41 Bn | 131.56 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 86.14 Bn | 78.15 Bn | 3.93 Bn | 0.05 |
| 3 | Argenx Se | 65.52 Bn | 60.34 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.21 Bn | 53.07 Bn | 52.00 Mn | 0.05 |
| 5 | BeOne Medicines | 42.15 Bn | 37.05 Bn | 1.53 Bn | 0.12 |
| 6 | Alnylam Pharmaceuticals | 31.62 Bn | 28.31 Bn | 992.69 Mn | - |
| 7 | BioNTech SE | 27.95 Bn | 9.56 Bn | 668.28 Mn | 0.03 |
| 8 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | 0.26 |
| 9 | Royalty Pharma | 27.30 Bn | 26.46 Bn | - | 0.47 |
| 10 | In8Bio | 23.46 Mn | 23.46 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2021 | 0.01 |
| Dec 31, 2020 | 0.01 |